Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.
Аннотация
Idiopathic multicentric Castleman disease (iMCD) is rare and life-threatening; although siltuximab is standard first-line therapy, a substantial proportion of patients are refractory or experience relapse. We report a 31-year-old woman with HHV-8-negative iMCD with idiopathic plasmacytic lymphadenopathy (IPL; iMCD-IPL), intractable to five prior lines of therapy, who declined siltuximab and enrolled in ChiCTR1900025419. After fludarabine/cyclophosphamide lymphodepletion, she received 1 × 106 CAR + T cells/kg of autologous CD19 CAR T cells on day 0. Grade 1 cytokine release syndrome (Tmax 38.2°C) resolved with supportive care; no ICANS occurred. CAR transgene levels expanded (peaking on day +11) and remained detectable through day +58, and flow cytometry showed CD19+ B-cell depletion from day +7 to day +198. By day +198, she met CDCN criteria for complete biochemical and clinical response with normalization of inflammatory markers and hematologic recovery. Panhypogammaglobulinemia was managed with intravenous immunoglobulin replacement. At > 12 months post-infusion, she remains in complete, treatment-free remission. This observation supports a B-cell-centric model for refractory iMCD-IPL and motivates prospective evaluation of CD19 CAR T-cell therapy.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.